company background image
AKLI logo

Akili NasdaqCM:AKLI Stock Report

Last Price

US$0.43

Market Cap

US$34.0m

7D

-0.6%

1Y

-62.8%

Updated

02 Jul, 2024

Data

Company Financials +

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

AKLI Stock Overview

A digital medicine company, develops cognitive treatments through game-changing technologies.

AKLI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Akili, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Akili
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$1.25
52 Week LowUS$0.19
Beta1.72
11 Month Change2.71%
3 Month Change71.16%
1 Year Change-62.76%
33 Year Change-95.70%
5 Year Changen/a
Change since IPO-95.73%

Recent News & Updates

Recent updates

Akili surges 21% as Singapore investment firms take joint stake

Aug 26

Shareholder Returns

AKLIUS Healthcare ServicesUS Market
7D-0.6%0.5%-2.1%
1Y-62.8%-20.3%19.0%

Return vs Industry: AKLI underperformed the US Healthcare Services industry which returned -22.7% over the past year.

Return vs Market: AKLI underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is AKLI's price volatile compared to industry and market?
AKLI volatility
AKLI Average Weekly Movement21.3%
Healthcare Services Industry Average Movement8.2%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: AKLI's share price has been volatile over the past 3 months.

Volatility Over Time: AKLI's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201168Matt Franklinwww.akiliinteractive.com

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization.

Akili, Inc. Fundamentals Summary

How do Akili's earnings and revenue compare to its market cap?
AKLI fundamental statistics
Market capUS$34.01m
Earnings (TTM)-US$48.54m
Revenue (TTM)US$1.95m

17.5x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKLI income statement (TTM)
RevenueUS$1.95m
Cost of RevenueUS$855.00k
Gross ProfitUS$1.09m
Other ExpensesUS$49.64m
Earnings-US$48.54m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin56.11%
Net Profit Margin-2,492.04%
Debt/Equity Ratio22.5%

How did AKLI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.